.png){kind=logo}
-
FHU - INFIRE « INnovation Fibrosis Inflammation REmodeling »
The University Hospital Federation (FHU) INFIRE – INnovation Fibrosis Inflammation REmodeling has been accredited by the Assistance Publique – Hôpitaux de Paris (AP-HP), Inserm, and the Universities of Île-de-France for 5 years (2025-2029).
Coordinated at Bichat Hospital by Professor Raphaël Borie, Dr. Camille Cohen and Professor Grégory Ducrocq, the FHU INFIRE is committed to a dynamic of synergy between care, research, and teaching to address major medical challenges.
The FHU INFIRE aims to improve the management of inflammatory and fibrosing diseases, whether cardiac, vascular, joint, renal, or pulmonary, by relying on close collaboration between clinicians, researchers, academics, and industrial partners.
The complex challenges posed by fibrosis and tissue remodeling constitute major obstacles in healthcare, with therapeutic options still limited.
By promoting the integration of hospital and academic expertise, the FHU INFIRE aims to promote early diagnosis, deepen understanding of the causes of fibrosis and remodeling, and identify targeted therapies.
Find more information on the page Linkedin INFIRE
-
FHU-MOSAIC
FHU-MOSAIC
The FHU Mosaic (Multiscale Optimized Strategy for Artificial intelligence-based Imaging biomarkers in digestive Cancer) is a transdisciplinary federation involving a collaborative network of clinical teams, research and industry. It involves 4 teams at Inserm level, including 3 from UMRS 1149 CRI: Team INDiD (V. Paradis), Team LBI (B. Van Beers) and Team GeNeHetX (R. Nicolle).
Mosaic aims to identify prognostic and theranostic biomarkers of digestive tumors (hepatocellular carcinomas and digestive neuro-endocrine tumors) by developing an approach multi-parametric multi-scale imaging, combining radiology (macroscopy), pathology (microscopy and molecular) and nuclear medicine (functional): IMAGOMICS. Using Artificial Intelligence (AI) methods, this project combines the multiple facets of tumor imaging to improve tumor characterization and disease monitoring. Thus, Mosaic participates in the development of non-invasive diagnostic, prognostic and theranostic modalities through virtual biopsy. Mosaic can be contacted through its project manager K. Mondet using the contact form available on the website.